Microvast Holdings announces departure of chief financial officer
CAMBRIDGE, Mass.—Robert L. Zerbe, a director at Vericel Corp (NASDAQ:VCEL), executed a sale of 2,500 shares of the company’s common stock on February 5, according to a recent SEC filing. The shares were sold at an average price of $62.50 each, resulting in a total transaction value of $156,250. This sale was conducted under a Rule 10b5-1 trading plan, which Zerbe adopted in March 2024. The transaction occurred as the stock trades near its 52-week high of $63, with InvestingPro data showing a strong 32% return over the past six months.
In a separate transaction on the same day, Zerbe acquired 2,500 shares through the exercise of stock options at a price of $13.05 per share. This acquisition, valued at $32,625, increased his direct ownership to 29,095 shares following the transactions. According to InvestingPro, the company currently commands a market capitalization of $2.88 billion, with analysts maintaining a bullish outlook on the stock.
Vericel, based in Cambridge, Massachusetts, specializes in the development and commercialization of advanced cell therapies for the treatment of severe diseases and conditions. The company has demonstrated robust growth with revenue increasing 22.5% in the last twelve months, maintaining a healthy gross profit margin of 71.5%.
In other recent news, Vericel Corporation’s financial performance has been a topic of interest among several analysts. Canaccord Genuity raised its price target for Vericel to $67, maintaining a Buy rating, following the company’s preannouncement of its Q4 2024 results and guidance for 2025. The firm’s analyst, Caitlin Cronin, cited strong mid-term targets related to margins and profitability as reasons for the increased price target. Vericel’s projected revenue for 2026 is estimated to reach $352.6 million, according to Cronin’s analysis.
In contrast, H.C. Wainwright reaffirmed a Buy rating and a $60.00 price target for Vericel, noting that the company’s Q4 2024 revenues fell slightly short of expectations. The company’s product, MACI, continues to be a key revenue contributor, with Q4 sales estimated between $68.2 million and $68.7 million. The firm also highlighted Vericel’s plans to submit an Investigational New Drug (IND) application for MACI Ankle in 2025.
Canaccord Genuity also restated their Buy rating on Vericel, despite the company’s Q4 revenue falling short of estimates. The firm noted that MACI product revenue surpassed their estimates, while revenues from Epicel and NexoBrid fell below expectations. For 2025, Vericel is projecting total revenue growth of 20-23%.
Lastly, Truist Securities upgraded its price target for Vericel to $67.00, expressing confidence in the company’s growth trajectory. The firm expects Vericel to see a 20% or more increase in revenue and profitability in the 2025-2026 period. These recent developments reflect a positive outlook on Vericel’s financial growth and product pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.